Craft

Nkarta Therapeutics

Stock Price

$10.8

2024-03-28

Market Capitalization

$761.3 M

2024-03-28

Nkarta Therapeutics Summary

Company Summary

Overview
Nkarta Therapeutics is a biopharmaceutical company developing engineered natural killer (NK) cell therapies for the treatment of cancer. The company combines its NK platform technology with cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body.
Type
Public
Status
Active
Founded
2015
HQ
South San Francisco, CA, US | view all locations
Website
https://www.nkartatx.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Paul Hastings

    Paul Hastings, Chief Executive Officer

    • Ralph Brandenberger

      Ralph Brandenberger, Vice President, Technical Operations

      • Alicia Hager

        Alicia Hager, Chief Legal Officer

        • Nadir Mahmood

          Nadir Mahmood, Chief Financial and Business Officer

          LocationsView all

          1 location detected

          • South San Francisco, CA HQ

            United States

            6000 Shoreline Ct #102

          Nkarta Therapeutics Financials

          Summary Financials

          Net income (FY, 2023)
          ($117.5M)
          Cash (FY, 2023)
          $31.0M
          EBIT (FY, 2023)
          ($131.7M)

          News

          Footer menu